RxDoctor Payments Data

Matthew McGuffee, NP

Family · Monroe, LANPI 1407348352

Payments from drug & device makers

$4,712in general payments, 2019–2025

Across 255 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Novartis$663
  • Merck$519
  • Johnson & Johnson$412
  • Amgen$410
  • Abbott$261
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$4,712100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,712 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$45,769
Medicare patients
395
Services billed
679

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban275$204,935
EntrestoSacubitril/Valsartan101$82,981
XareltoRivaroxaban25$18,718
BrilintaTicagrelor28$15,541
Repatha SureclickEvolocumab23$14,786
Ranolazine ErRanolazine26$2,315
Bumetanide43$2,085
Metoprolol Succinate120$1,889
ClopidogrelClopidogrel Bisulfate116$1,556
Losartan Potassium85$1,362
Atorvastatin Calcium99$1,350
Metoprolol Tartrate176$1,229
Rosuvastatin Calcium48$934
Carvedilol98$851
SotalolSotalol Hcl44$849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$115$204,935275 claims
NovartisEntresto$663$82,981101 claims
Johnson & JohnsonXarelto$412$18,71825 claims
AstraZenecaBrilinta$27$15,54128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,610 family providers in Louisiana.

Other family in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →